Tag: Immutep Limited
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Manufacturers should do this sooner rather than later, says precision engineer
Australian precision engineering and industrial instrumentation company CENMAC implemented ERP software when it was still a one-man operation. “I couldn’t imagine us growing to this size without MRPeasy,” says Jason Ford, Founder.
